Cataracts remain one of the most prevalent and debilitating eye conditions, often requiring surgical intervention to restore sight. Yet even after surgery, many patients develop anterior subcapsular ...

The Catalan biopharmaceutical company Ability Pharmaceuticals, SA (AbilityPharma), focused on the development of innovative oral autophagy-inducing anticancer compounds, announces a €7M ...

Cataracts are a leading cause of vision loss worldwide, and fibrosis-related complications after surgery often limit full ...

The molecular rules underlying autophagy of mitochondria, or mitophagy, provide therapeutic applications for neurodegeerative disease.

AbilityPharma is completing a Phase 2b clinical trial with ABTL0812 in metastatic pancreatic cancer (all 140 patients recruited) with the aim of demonstrating greater efficacy than standard ...